Iovance Biotherapeutics Inc (IOVA) stock has risen 0.64% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives IOVA stock a score of 34 out of a possible 100.
That rank is chiefly influenced by a short-term technical score of 20. IOVA's rank also includes a long-term technical score of 23. The fundamental score for IOVA is 60. In addition to the average rating from Wall Street analysts, IOVA stock has a mean target price of 50.2. This means analysts expect the stock to climb 39.37% over the next 12 months.
What's Happening with IOVA Stock Today
Iovance Biotherapeutics Inc (IOVA) stock has fallen -3.56% while the S&P 500 is down -0.15% as of 11:38 AM on Wednesday, Mar 3. IOVA is down -$1.33 from the previous closing price of $37.35 on volume of 640,448 shares. Over the past year the S&P 500 is higher by 28.67% while IOVA has risen 0.64%. IOVA lost -$1.88 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Iovance Biotherapeutics Inc (IOVA) Stock.
